Kaiser Germán G, Mucci Nicolás C, González Vega, Sánchez Lourdes, Parrón José A, Pérez María D, Calvo Miguel, Aller Juan F, Hozbor Federico A, Mutto Adrián A
Grupo de Biotecnología de la Reproducción, Instituto Nacional de Tecnología Agropecuaria, 7620 Balcarce, Argentina.
Grupo de Biotecnología de la Reproducción, Instituto Nacional de Tecnología Agropecuaria, 7620 Balcarce, Argentina.
J Dairy Sci. 2017 Mar;100(3):1605-1617. doi: 10.3168/jds.2016-11173. Epub 2017 Jan 18.
Lactoferrin and lysozyme are 2 glycoproteins with great antimicrobial activity, being part of the nonspecific defensive system of human milk, though their use in commercial products is difficult because human milk is a limited source. Therefore, many investigations have been carried out to produce those proteins in biological systems, such as bacteria, yeasts, or plants. Mammals seem to be more suitable as expression systems for human proteins, however, especially for those that are glycosylated. In the present study, we developed a bicistronic commercial vector containing a goat β-casein promoter and an internal ribosome entry site fragment between the human lactoferrin and human lysozyme genes to allow the introduction of both genes into bovine adult fibroblasts in a single transfection. Embryos were obtained by somatic cell nuclear transfer, and, after 6 transferences to recipients, 3 pregnancies and 1 viable bitransgenic calf were obtained. The presence of the vector was confirmed by fluorescent in situ hybridization of skin cells. At 13 mo of life and after artificial induction of lactation, both recombinant proteins were found in the colostrum and milk of the bitransgenic calf. Human lactoferrin concentration in the colostrum was 0.0098 mg/mL and that in milk was 0.011 mg/mL; human lysozyme concentration in the colostrum was 0.0022 mg/mL and that in milk was 0.0024 mg/mL. The molar concentration of both human proteins revealed no differences in protein production of the internal ribosome entry site upstream and downstream protein. The enzymatic activity of lysozyme in the transgenic milk was comparable to that of human milk, being 6 and 10 times higher than that of bovine lysozyme present in milk. This work represents an important step to obtain multiple proteins or enhance single protein production by using animal pharming and fewer regulatory and antibiotic-resistant foreign sequences, allowing the design of humanized milk with added biological value for newborn nutrition and development. Transgenic animals can offer a unique opportunity to the dairy industry, providing starting materials suitable to develop specific products with high added value.
乳铁蛋白和溶菌酶是两种具有强大抗菌活性的糖蛋白,它们是母乳非特异性防御系统的一部分,不过由于母乳来源有限,将它们用于商业产品存在困难。因此,人们进行了许多研究,试图在细菌、酵母或植物等生物系统中生产这些蛋白质。然而,哺乳动物似乎更适合作为人类蛋白质的表达系统,尤其是对于那些进行了糖基化修饰的蛋白质。在本研究中,我们构建了一种双顺反子商业载体,该载体含有山羊β-酪蛋白启动子以及人乳铁蛋白和人溶菌酶基因之间的内部核糖体进入位点片段,以便在一次转染中将这两个基因导入牛成纤维细胞。通过体细胞核移植获得胚胎,在将胚胎移植到受体动物6次后,成功获得了3次妊娠,并产下了1头存活的双转基因小牛。通过对皮肤细胞进行荧光原位杂交,证实了载体的存在。在小牛出生13个月并人工诱导泌乳后,在双转基因小牛的初乳和乳汁中均发现了这两种重组蛋白。初乳中乳铁蛋白的浓度为0.0098毫克/毫升,乳汁中为0.011毫克/毫升;初乳中溶菌酶的浓度为0.0022毫克/毫升,乳汁中为0.0024毫克/毫升。两种人类蛋白质的摩尔浓度显示,内部核糖体进入位点上游和下游蛋白质的产量没有差异。转基因牛奶中溶菌酶的酶活性与母乳相当,分别比牛奶中牛溶菌酶的活性高6倍和10倍。这项工作是通过利用动物制药技术获得多种蛋白质或提高单一蛋白质产量的重要一步,同时减少了调控序列和抗生素抗性外源序列,从而能够设计出具有更高生物学价值的人乳化牛奶,用于新生儿营养和发育。转基因动物可为乳制品行业提供独特的机遇,提供适合开发高附加值特定产品的原材料。